National Bank of Austria   Report issue

Foundation Phase 1 Phase 2 Phase 4
Founded: Vienna Austria (1816)

Organization Overview

First Clinical Trial
2004
NCT01867645
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (3)

calcium (1 trial)

strontium ranelate (Protelos) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (1)

fatty acid (1 trial)

Drugs in Phase 1 Trials (2)

albumin (Human) (Plasbumin) (1 trial)

igm enriched immunoglobulins (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Diseases, Metabolic (Phase 4)

Critical Illness (Phase 1)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Primary (Phase 4)

Inflammation (Phase 2)

Multiple Organ Failure (Phase 1)

Muscular Diseases (Phase 1)

Obesity (Phase 2)

Obesity, Morbid (Phase 2)

Osteoporosis (Phase 4)

Polyneuropathies (Phase 1)

Sepsis (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 6